Synthesis and evaluation of [(1R)-1-amino-2-(2,5-difluorophenyl)ethyl] cyclohexanes and 4-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]piperidines as DPP-4 inhibitors

被引：15

作者：

Chen, Ping ^{[1
]}

Caldwell, Charles G. ^{[1
]}

Ashton, Wallace ^{[1
]}

Wu, Joseph K. ^{[2
]}

He, Huaibing ^{[1
]}

Lyons, Kathryn A. ^{[1
]}

Thornberry, Nancy A. ^{[2
]}

Weber, Ann E. ^{[1
]}

机构：

[1] Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA

[2] Merck Res Labs, Dept Metab Disorders Diabet, Rahway, NJ 07065 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 06期

关键词：

DIPEPTIDYL-PEPTIDASE-IV; GLUCAGON-LIKE PEPTIDE-1; SITAGLIPTIN; DISCOVERY; HOMOLOG; POTENT;

D O I：

10.1016/j.bmcl.2010.12.060

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of 4-amino cyclohexanes and 4-substituted piperidines were prepared and evaluated for inhibition of DPP-4. Analog 20q displayed both good DPP-4 potency and selectivity against other proteases, while derivative 20k displayed long half life and modest oral bioavailability in rat. The most potent analog, 3-(5-aminocarbonylpyridyl piperidine 53j, displayed excellent DPP-4 activity with good selectivity versus other proline enzymes. Published by Elsevier Ltd.

引用

收藏

页码：1880 / 1886

页数：7

相关论文

共 22 条

[11] (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [J].

Kim, D ;

Wang, LP ;

Beconi, M ;

Eiermann, GJ ;

Fisher, MH ;

He, HB ;

Hickey, GJ ;

Kowalchick, JE ;

Leiting, B ;

Lyons, K ;

Marsilio, F ;

McCann, ME ;

Patel, RA ;

Petrov, A ;

Scapin, G ;

Patel, SB ;

Roy, RS ;

Wu, JK ;

Wyvratt, MJ ;

Zhang, BB ;

Zhu, L ;

Thornberry, NA ;

Weber, AE .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (01) :141-151

[12] Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - Potential importance of selectivity over dipeptidyl peptidases 8 and 9 [J].

Lankas, GR ;

Leiting, B ;

Roy, RS ;

Eiermann, GJ ;

Beconi, MG ;

Biftu, T ;

Chan, CC ;

Edmondson, S ;

Feeney, WP ;

He, HB ;

Ippolito, DE ;

Kim, D ;

Lyons, KA ;

Ok, HO ;

Patel, RA ;

Petrov, AN ;

Pryor, KA ;

Qian, XX ;

Reigle, L ;

Woods, A ;

Wu, JK ;

Zaller, D ;

Zhang, XP ;

Zhu, L ;

Weber, AE ;

Thornberry, NA .

DIABETES, 2005, 54 (10) :2988-2994

[13] Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII [J].

Leiting, B ;

Pryor, KD ;

Wu, JK ;

Marsilio, F ;

Patel, RA ;

Craik, CS ;

Ellman, JA ;

Cummings, RT ;

Thornberry, NA .

BIOCHEMICAL JOURNAL, 2003, 371 (02) :525-532

[14]

Lu YX, 2001, SYNTHESIS-STUTTGART, P1639

[15] Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV [J].

Olsen, C ;

Wagtmann, N .

GENE, 2002, 299 (1-2) :185-193

[16] 4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors [J].

Parmee, ER ;

He, JF ;

Mastracchio, A ;

Edmondson, SD ;

Colwell, L ;

Eiermann, G ;

Feeney, WP ;

Habulihaz, B ;

He, HB ;

Kilburn, R ;

Leiting, B ;

Lyons, K ;

Marsilio, F ;

Patel, RA ;

Petrov, A ;

Di Salvo, J ;

Wu, JK ;

Thornberry, NA ;

Weber, AE .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (01) :43-46

[17] Proyl peptidases: a serine protease subfamily with high potential for drug discovery [J].

Rosenblum, JS ;

Kozarich, JW .

CURRENT OPINION IN CHEMICAL BIOLOGY, 2003, 7 (04) :496-504

[18] Discovery of JANUVIA™ (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type2 diabetes [J].

Thornberry, Nancy A. ;

Weber, Ann E. .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2007, 7 (06) :557-568

[19]

Vahl TP, 2004, EXPERT OPIN INV DRUG, V13, P177, DOI 10.1517/eoid.13.3.177.27346

[20] Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors [J].

Verspohl, E. J. .

PHARMACOLOGY & THERAPEUTICS, 2009, 124 (01) :113-138